Corcept Therapeutics
CORT
52 hedge funds and large institutions have $108M invested in Corcept Therapeutics in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 6 closing their positions.
11% more capital invested
Capital invested by funds: $97.5M → $108M (+$10.4M)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 55 → 52 (-3)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$577K |
| 2 |
MC
Menta Capital
San Francisco,
California
|
+$254K |
| 3 |
ISL
Ingalls & Snyder LLC
New York
|
+$224K |
| 4 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
+$182K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$1.45M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$376K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$134K |
| 4 |
SB
Suntrust Banks
Atlanta,
Georgia
|
-$110K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$96.4K |
CORT Hedge Fund Activity: Q4 2014 in Review
52 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2014, worth a combined $108M — up 11% from $97.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CORT and 4 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 17 added.
The largest buyer was BlackRock Fund Advisors, adding an estimated $577K. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $1.45M sold.
- 52 institutional investors held Corcept Therapeutics (CORT) as of Q4 2014, down from 55 in Q3 2014.
- Funds reported $108M of Corcept Therapeutics stock for Q4 2014, up 11% quarter-over-quarter.
- 4 funds opened new Corcept Therapeutics positions in Q4 2014 and 6 closed out, a net change of -2 holders.
- The largest Corcept Therapeutics buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $577K added.
- The largest Corcept Therapeutics seller in Q4 2014 was Catalyst Capital Advisors, an estimated $1.45M sold.
Based on aggregated 13F filings for Q4 2014.